Saturday, September 01, 2007 5:42:03 PM
>it’s conservative to assume that GTC stands to earn a mid-single-digit royalty on the sales of Protexia.<
Each time I spoke with Tom Newberry at the annual meetings, I mentioned the possibility of franchising the goats and/or GTC's expertise (ala Mickey Dees/Burger King). Such an idea
I've decided to request equity participation/stock options- Should we take a poll - LOL
In regards to Bio-Defense - whatever happened to this??
>GTC BIOTHERAPEUTICS AND USAMRIID TO COOPERATIVELY STUDY ATryn® FOR VIRAL HEMORRHAGIC DISEASES
FRAMINGHAM, MA - October 18, 2004 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has signed a two-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of ATryn® to hemorrhagic diseases resulting from infections of the Ebola and Marburg viruses. Under the CRADA, GTC will supply ATryn®, its recombinant form of human antithrombin, for in vitro and preclinical studies developed by the USAMRIID. USAMRIID will perform all work associated with the live viruses.
"We believe that ATryn® has broad therapeutic potential in situations where antithrombin deficiency may be part of the progression of the disease," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and Chief Executive Officer. "This CRADA allows for further evaluation of ATryn®'s therapeutic potential while GTC continues in discussions with potential commercial development partners."<
http://www.transgenics.com/pressreleases/pr101804.html
Each time I spoke with Tom Newberry at the annual meetings, I mentioned the possibility of franchising the goats and/or GTC's expertise (ala Mickey Dees/Burger King). Such an idea
I've decided to request equity participation/stock options- Should we take a poll - LOL
In regards to Bio-Defense - whatever happened to this??
>GTC BIOTHERAPEUTICS AND USAMRIID TO COOPERATIVELY STUDY ATryn® FOR VIRAL HEMORRHAGIC DISEASES
FRAMINGHAM, MA - October 18, 2004 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has signed a two-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of ATryn® to hemorrhagic diseases resulting from infections of the Ebola and Marburg viruses. Under the CRADA, GTC will supply ATryn®, its recombinant form of human antithrombin, for in vitro and preclinical studies developed by the USAMRIID. USAMRIID will perform all work associated with the live viruses.
"We believe that ATryn® has broad therapeutic potential in situations where antithrombin deficiency may be part of the progression of the disease," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and Chief Executive Officer. "This CRADA allows for further evaluation of ATryn®'s therapeutic potential while GTC continues in discussions with potential commercial development partners."<
http://www.transgenics.com/pressreleases/pr101804.html
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
